



We
follow the
science



and put
patients
first

Development Pipeline as at 10 February 2026

Key

 Partnered product

AstraZeneca-sponsored or -directed trial New Molecular Entities (NMEs) and significant indications

Anticipated data timing and submission status is provided for assets in Phase III or beyond. As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Phase I

Compound	Mechanism	Additional Information	Area Under Investigation
Oncology			
AZD0240	KRAS G12D armoured TCR-T		solid tumours
AZD0516	STEAP2 TOP1i ADC		prostate cancer
AZD0754	STEAP2 CAR-T		prostate cancer
AZD2068	EGFR/cMET actinium radioconjugate		solid tumours
AZD2284	STEAP2 actinium radioconjugate		prostate cancer
AZD2962	IRAK4 inhibitor		haematological malignancies
AZD3632	MENIN inhibitor		haematological malignancies
AZD4360	CLDN18.2 TOP1i ADC		solid tumours
AZD4512	CD22 TOP1i ADC	Modular Ph I/II open-label multi-center study	relapsed/refractory B-cell non-Hodgkin lymphoma
AZD5492	CD20 TITAN T-cell engager		haematology
AZD5863	CLDN18.2/CD3 bispecific antibody		solid tumours
AZD6621	STEAP2 T-cell engager		prostate cancer
AZD6750	CD8-guided IL2		solid tumours
AZD7003 (China)	GPC3 CAR-T		hepatocellular carcinoma/squamous non-small cell lung cancer
AZD8421	CDK2 inhibitor		solid tumours
AZD9750	AR PROTAC		prostate cancer
AZD9793	GPC3 T-cell engager		solid tumours
NT-112	KRAS G12D armoured TCR-T		solid tumours
NT-175	TP53 R175H armoured TCR-T		solid tumours
surovatamig	CD19/CD3 T-cell engager		r/r B-cell non-Hodgkin lymphoma
surovatamig SOUNDTRACK-E	CD19/CD3 T-cell engager		mature B-cell malignancies
volrustomig + lenvatinib	PD-1/CTLA-4 bispecific mAb + VEGFi		advanced renal cell carcinoma
volrustomig eVOLVE-RCC02	PD-1/CTLA-4 bispecific mAb		1L advanced clear cell renal cell carcinoma
CVRM			
AZD1613	PAPPA-1 mAb		ADPKD
AZD1705	lipid lowering		cardiovascular disease
AZD3974	anti-inflammatory and anti-fibrotic mechanism		cirrhosis
AZD4063	PLN		R14del dilated cardiomyopathy
AZD4144	NLRP3		cardiorenal disease
AZD4248	NNMT inhibitor		cardiorenal disease
AZD4954	Lp(a) inhibitor		dyslipidaemia
Respiratory & Immunology			
AZD0120	CD19/BCMA CAR-T		systemic lupus erythematosus
AZD0120	CD19/BCMA CAR-T		autoimmune diseases
AZD0120	CD19/BCMA CAR-T		multiple sclerosis
AZD5492	CD20 TITAN T-cell engager		systemic lupus erythematosus
AZD6912	siRNA		rheumatoid arthritis
AZD8965	inhibition of arginase enzyme		idiopathic pulmonary fibrosis
surovatamig	CD19/CD3 T-cell engager		B-cell driven autoimmune disease

Development Pipeline *continued*

Phase I *continued*

Compound	Mechanism	Additional Information	Area Under Investigation
Rare Disease			
ALXN2080	oral factor D inhibitor		healthy volunteers
ALXN2350 DCMRestore	AAV gene therapy		BAG3-associated dilated cardiomyopathy
AZD0120 ALACRITY	CD19/BCMA CAR-T		amyloid light-chain amyloidosis
AZD1390 AGILE	ATM inhibitor		glioblastoma

Phase II

Compound	Mechanism	Additional Information	Area Under Investigation
Oncology			
AZD0120	CD19/BCMA CAR-T		multiple myeloma
AZD0305	GPRC5D MMAE ADC		relapsed/refractory multiple myeloma
AZD3470	PRMT5 inhibitor	cHL (Phase II), solid tumours (Phase I)	classic Hodgkin lymphoma, solid tumours
AZD9574	PARP1 inhibitor		advanced solid malignancies
camizestrant	ngSERD		HR+ HER2- breast cancer
FPI-2265	PSMA actinium radioconjugate	PP	prostate cancer
IPH5201 + <i>Imfinzi</i>	CD39 mAb + PD-L1 mAb	PP	neoadjuvant/adjuvant NSCLC
puxitatum samrotecan	B7-H4 TOP1i ADC		solid tumours
rilvegostomig ARTEMIDE-01	PD-1/TIGIT bispecific mAb	PP	solid tumours
saruparib	PARP1 inhibitor		solid tumours
sonesitatum vedotin	CLDN18.2 MMAE ADC		solid tumours
surovatamig SOUNDTRACK-B	CD19/CD3 T-cell engager		B-cell non-Hodgkin lymphoma
surovatamig SYRUS	CD19/CD3 T-cell engager		B-cell acute lymphoblastic leukaemia
tilatamig samrotecan	EGFR/cMET TOP1i ADC		solid tumours
torvutatug samrotecan (AZD5335)	anti-FR α TOP1i ADC		ovarian cancer, solid tumours
volrustomig	PD-1/CTLA-4 bispecific mAb		solid tumours
volrustomig CANTOR	PD-1/CTLA-4 bispecific mAb		colorectal cancer (mCRC)
volrustomig eVOLVE-01	PD-1/CTLA-4 bispecific mAb		NSCLC
volrustomig eVOLVE-02	PD-1/CTLA-4 bispecific mAb		cervical cancer, head and neck squamous cell carcinoma
CVRM			
AZD2389	anti-fibrotic mechanism		metabolic dysfunction-associated steatohepatitis
AZD5462	RXFP1 agonist	PP	heart failure
AZD6234	peptide		chronic weight management in overweight or obesity
AZD9550 + AZD6234	GLP-1R glucagon dual agonist + selective amylin agonist		obesity
balcirenone/dapagliflozin	MR antagonist/modulator + SGLT2 inhibitor		CKD
elecglipron (AZD5004)	oral GLP-1 receptor agonist		T2D/chronic weight management
opemalirsen	podocyte health		nephropathy

Development Pipeline *continued*

Phase II *continued*

Compound	Mechanism	Additional Information	Area Under Investigation
Respiratory & Immunology			
atuliflapon	FLAP inhibitor		asthma
AZD1163	anti-PAD2/4 bispecific antibody		rheumatoid arthritis
AZD4604	inhaled JAK1 inhibitor		asthma
AZD6793	IRAK4 inhibitor		COPD
AZD7798	humanised monoclonal antibody targets T-cells subset		Crohn's disease
AZD8630	inhaled TSLP FAb	PP	asthma
tozorakimab	IL-33 mAb		asthma
Vaccines & Immune Therapies			
AZD0292	pseudomonas Psl-PcrV bispecific mAb		bronchiectasis
AZD5148	anti-clostridioides difficile TcdB mAb		reduction of <i>C. diff</i> recurrence
AZD7760	mAb combination targeting <i>S aureus</i> virulence factors		prevention of <i>Staph aureus</i> infection
Rare Disease			
ALXN1920 AUTUMN	kidney-targeted factor H fusion protein		primary membranous nephropathy
ALXN2030 CONCORD	siRNA targeting complement C3		antibody mediated rejection
ALXN2420 ASTERIA	growth hormone receptor antagonist		acromegaly
tarperprumig I TRANSCEND	kinase inhibitor		ANCA-associated vasculitis

Phase III/Pivotal Phase II/Registration (listed until launched in all applicable major markets)

Compound	Mechanism	Additional Information	Area Under Investigation	Data readout/ submission status
Oncology				
camizestran + CDK4/6i SERENA-6	ngSERD + CDK4/6i		1L HR+ HER2- ESR1m advanced breast cancer	Accepted
camizestran + palbociclib SERENA-4	ngSERD + CDK4/6i		1L HR+ HER2- advanced breast cancer	H2 2026
camizestran +/- abemaciclib CAMBRIA-2	ngSERD + CDK4/6i		adjuvant HR+ HER2- early breast cancer	>2027
camizestran CAMBRIA-1	ngSERD		adjuvant switch HR+ HER2- early breast cancer	2027
<i>Imfinzi</i> + <i>Imjudo</i> HIMALAYA	PD-L1 mAb + CTLA-4 mAb		1L unresectable HCC	Launched
<i>Imfinzi</i> +/- oleclumab +/- monalizumab PACIFIC-9	PD-L1 mAb +/- CD73 mAb +/- NKG2A mAb	PP	unresectable stage III NSCLC	H2 2026
puxitatug samrofecan Bluestar-Endometrial01	B7-H4 TOP1i ADC		2-3L B7-H4+ endometrial cancer	2027
rilvegostomig + bevacizumab +/- <i>Imjudo</i> ARTEMIDE-HCC01	PD-1/TIGIT bispecific mAb +VEGFi +/- CTLA-4 mAb	PP	1L HCC	>2027
rilvegostomig + CTx ARTEMIDE-Biliary01	PD-1/TIGIT bispecific mAb + CTx	PP	adjuvant biliary tract cancer	>2027
rilvegostomig + CTx ARTEMIDE-Lung02	PD-1/TIGIT bispecific mAb + CTx	PP	1L PD-L1 TC ≥1% SQ NSCLC	>2027
rilvegostomig + <i>Enhertu</i> ARTEMIDE-Gastric01	PD-1/TIGIT bispecific mAb + HER2 TOP1i ADC	PP	1L HER2+ gastric cancer	>2027
rilvegostomig ARTEMIDE-Biliary02	PD-1/TIGIT bispecific mAb	PP	metastatic biliary tract cancer	>2027
rilvegostomig ARTEMIDE-Lung03	PD-1/TIGIT bispecific mAb	PP	1L PD-L1 TC ≥1% NSQ NSCLC	>2027

Development Pipeline *continued*

Phase III/Pivotal Phase II/Registration (listed until launched in all applicable major markets) *continued*

Compound	Mechanism	Additional Information	Area Under Investigation	Data readout/ submission status
rilvegostomig ARTEMIDE-Lung04	PD-1/TIGIT bispecific mAb	PP	1L PD-L1 \geq 50% NSCLC	>2027
saruparib + ADT +/- abiraterone EvoPAR-Prostate02	PARP1 inhibitor + ADT +/- NHA		localised/locally advanced BRCAm prostate cancer	>2027
saruparib + camizestrant EvoPAR-Breast01	PARP1 inhibitor + ngSERD		BRCA/PALB2m HR+ HER2- metastatic breast cancer	>2027
saruparib + NHA EvoPAR-Prostate01	PARP1 inhibitor + NHA		HRRm/non-HRRm mCSPC	>2027
sonesitatur vedotin CLARITY-Gastric01	CLDN18.2 MMAE ADC		2L+ CLDN18.2+ gastric cancer	H1 2026
surovatamig SOUNDTRACK-D2	CD19/CD3 T-cell engager		1L elderly DLBCL	>2027
surovatamig SOUNDTRACK-F1	CD19/CD3 T-cell engager		follicular lymphoma	>2027
torvutatug samrotecan (AZD5335) TREVI-OC-01	anti-FR α TOP1i ADC		ovarian cancer	>2027
volrustomig eVOLVE-Cervical	PD-1/CTLA-4 bispecific mAb		high-risk locally advanced cervical cancer	2027
volrustomig eVOLVE-HNSCC	PD-1/CTLA-4 bispecific mAb		unresected locally advanced head and neck squamous cell carcinoma	>2027
volrustomig eVOLVE-Lung02	PD-1/CTLA-4 bispecific mAb		1L metastatic NSCLC	2027
volrustomig eVOLVE-Meso	PD-1/CTLA-4 bispecific mAb		1L unresectable malignant pleural mesothelioma	>2027
volrustomig eVOLVE-Meso	PD-1/CTLA-4 bispecific mAb		1L unresectable malignant pleural mesothelioma	>2026
CVRM				
balcinrenone/dapagliflozin	MR antagonist/modulator + SGLT2 inhibitor		heart failure with CKD	2027
baxdrostat BaxHTN Bax24 BaxAsia	aldosterone synthase inhibitor		hypertension	Accepted
baxdrostat BaxPA	aldosterone synthase inhibitor		primary aldosteronism	>2027
baxdrostat/dapagliflozin	aldosterone synthase inhibitor and reversible inhibitor of SGLT2		CKD	>2027
baxdrostat/dapagliflozin	aldosterone synthase inhibitor and reversible inhibitor of SGLT2		prevention of heart failure	>2027
laroprovstat AZURE	PCSK9 inhibitor		dyslipidaemia	2027
<i>Wainua</i>	ligand-conjugated antisense	PP	patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)	Launched
zibotentan/dapagliflozin	endothelin A receptor antagonist/ SGLT2 inhibitor		CKD with high proteinuria	2027
Respiratory & Immunology				
<i>Saphnelo</i> TULIP 1 & TULIP 2 AZALEA (China)	type I IFN receptor mAb	PP	systemic lupus erythematosus	Launched
<i>Tezspire</i> NAVIGATOR DIRECTION (China)	TSLP mAb	PP	severe uncontrolled asthma	Launched
tozorakimab OBERON TITANIA PROSPERO MIRANDA	IL-33 mAb		chronic obstructive pulmonary disease	H1 2026
tozorakimab TILIA	IL-33 mAb		severe viral lower respiratory tract disease	H2 2026
Vaccines & Immune Therapies				
<i>Kavigale</i> SUPERNOVA	SARS-CoV-2 LAAB		prevention of COVID-19	Launched

Development Pipeline *continued*

Compound	Mechanism	Additional Information	Area Under Investigation	Data readout/ submission status
Rare Disease				
anselamimab CARES	fibril-reactive mAb		amyloid light-chain amyloidosis	Accepted
clirimitug DepleTTR-CM	transthyretin depleter	PP	transthyretin amyloid cardiomyopathy	2027
efzimfotase alfa HICKORY (301), MULBERRY (305), CHESTNUT (303)	next generation TNSALP ERT		hypophosphatasia	H1 2026
eneboparatide CALYPSO	parathyroid hormone receptor 1		hypoparathyroidism	Q1 2025
gefurulimab PREVAIL	novel anti-C5, dual binding, nanobody		generalised myasthenia gravis	Accepted

Additional Information

Significant Life-cycle Management

Anticipated data timing and submission status is provided for assets in Phase III or beyond. Projects in Phase III unless otherwise noted.

Compound	Mechanism	Additional Information	Area Under Investigation	Data readout/ submission status
Oncology				
<i>Calquence</i> + R-CHOP ESCALADE	BTK inhibitor + R-CHOP		1L DLBCL	2027
<i>Calquence</i> + venetoclax + obinutuzumab AMPLIFY	BTK inhibitor + BCL-2 inhibitor + anti-CD20 mAb		1L CLL	Launched
<i>Calquence</i> ECHO	BTK inhibitor	PP	1L MCL	Launched
<i>Datroway</i> + <i>Imfinzi</i> + CTx AVANZAR	TROP2 TOP1i ADC + PD-L1 mAb + CTx	PP	1L NSQ/NSQ TROP2+ NSCLC	H2 2026
<i>Datroway</i> + <i>Imfinzi</i> TROPION-Breast04	TROP2 TOP1i ADC + PD-L1 mAb	PP	neo/adjuvant TNBC or HR-low/HER2- breast cancer	>2027
<i>Datroway</i> + <i>Imfinzi</i> TROPION-Breast05	TROP2 TOP1i ADC + PD-L1 mAb	PP	1L PD-L1 CPS \geq 10 TNBC	2027
<i>Datroway</i> + pembrolizumab TROPION-Lung07	TROP2 TOP1i ADC + PD-1 mAb	PP	1L PD-L1 <50% NSQ NSCLC	H2 2026
<i>Datroway</i> + pembrolizumab TROPION-Lung08	TROP2 TOP1i ADC + PD-1 mAb	PP	1L PD-L1 TPS \geq 50% NSQ NSCLC	H2 2026
<i>Datroway</i> + rilvegostomig TROPION-Lung10	TROP2 TOP1i ADC + PD-1/TIGIT bispecific mAb	PP	1L PD-L1 \geq 50% NSQ NSCLC	>2027
<i>Datroway</i> + <i>Tagrisso</i> TROPION-Lung14	TROP2 TOP1i ADC + EGFR TKI	PP	1L EGFRm NSCLC	>2027
<i>Datroway</i> + <i>Tagrisso</i> TROPION-Lung15	TROP2 TOP1i ADC + EGFR TKI	PP	2L EGFRm NSCLC	H2 2026
<i>Datroway</i> +/- <i>Imfinzi</i> TROPION-Breast03	TROP2 TOP1i ADC +/- PD-L1 mAb	PP	post-neoadjuvant TNBC with residual disease	2027
<i>Datroway</i> TROPION-Breast02	TROP2 TOP1i ADC	PP	1L TNBC not candidates for IO	Accepted
<i>Datroway</i> TROPION-Lung05	TROP2 TOP1i ADC	PP	advanced or metastatic EGFRm NSCLC progressed on prior systemic therapies including TKIs and platinum-based chemotherapy	Launched
<i>Enhertu</i> (platform) DESTINY-Breast07	HER2 TOP1i ADC	PP	Phase II LCM	HER2+ breast cancer
<i>Enhertu</i> + rilvegostomig DESTINY-BTC01	HER2 TOP1i ADC + PD-1/TIGIT bispecific mAb	PP	1L HER2+ biliary tract cancer	>2027
<i>Enhertu</i> + rilvegostomig/ pembrolizumab DESTINY-Endometrial01	HER2 TOP1i ADC + PD-1/TIGIT bispecific mAb/PD-1 mAb	PP	1L HER2+ pMMR endometrial cancer	>2027
<i>Enhertu</i> + pertuzumab DESTINY-Breast09	HER2 TOP1i ADC	PP	1L HER2+ breast cancer	Launched

Development Pipeline *continued*

Significant Life-cycle Management *continued*

Compound	Mechanism	Additional Information	Area Under Investigation	Data readout/ submission status
<i>Enhertu</i> DESTINY-Breast05	HER2 TOP1i ADC	PP	post-neoadjuvant high-risk HER2+ early breast cancer	Q3 2025
<i>Enhertu</i> DESTINY-Breast06	HER2 TOP1i ADC	PP	post-ET HR+ HER2-low/ultralow breast cancer	Launched
<i>Enhertu</i> DESTINY-Endometrial02	HER2 TOP1i ADC	PP	adjuvant endometrial cancer	>2027
<i>Enhertu</i> DESTINY-Gastric04	HER2 TOP1i ADC	PP	2L HER2+ gastric cancer	Launched
<i>Enhertu</i> DESTINY-Lung04	HER2 TOP1i ADC	PP	1L HER2m NSCLC	H1 2026
<i>Enhertu</i> DESTINY-PanTumor03 (China)	HER2 TOP1i ADC	PP Phase II LCM	HER2 expressing solid tumours	
<i>Enhertu</i> followed by THP DESTINY-Breast11	HER2 TOP1i ADC	PP	neoadjuvant high-risk HER2+ early breast cancer	Accepted
<i>Enhertu</i> DESTINY-PanTumor01	HER2 TOP1i ADC	PP Phase II LCM	HER2m solid tumours	
<i>Enhertu</i> DESTINY-PanTumor02	HER2 TOP1i ADC	PP Phase II LCM	HER2 expressing solid tumours	Launched
<i>Imfinzi</i> + BCG POTOMAC	PD-L1 mAb + BCG		non-muscle invasive bladder cancer	Accepted
<i>Imfinzi</i> + CRT KUNLUN	PD-L1 mAb + CRT		locally advanced ESCC	H2 2026
<i>Imfinzi</i> + CRT PACIFIC-5 (China)	PD-L1 mAb + CRT	PP	locally advanced stage III NSCLC	Launched
<i>Imfinzi</i> + CTx +/- <i>Lynparza</i> DUO-E	PD-L1 mAb + CTx +/- PARP inhibitor	PP	1L endometrial cancer	Launched
<i>Imfinzi</i> + CTx NIAGARA	PD-L1 mAb + CTx		muscle invasive bladder cancer (cis-eligible)	Launched
<i>Imfinzi</i> + domvanalimab following cCRT PACIFIC-8	PD-L1 mAb + TIGIT following cCRT	PP	unresectable stage III NSCLC	>2027
<i>Imfinzi</i> + EV +/- <i>Imjudo</i> VOLGA	PD-L1 mAb + nectin-4 targeting MMAE ADC +/- CTLA-4 mAb		muscle invasive bladder cancer (cis- ineligible/refusal)	H1 2026
<i>Imfinzi</i> + FLOT MATTERHORN	PD-L1 mAb + CTx	PP	resectable early gastric cancer	Launched
<i>Imfinzi</i> + <i>Imjudo</i> + SoC NILE	PD-L1 mAb + CTLA-4 mAb + SoC		1L urothelial cancer	H1 2026
<i>Imfinzi</i> + <i>Imjudo</i> + TACE +/- lenvatinib EMERALD-3	PD-L1 mAb + CTLA-4 mAb +/- chemoembolisation +VEGFi		locoregional HCC	H1 2026
<i>Imfinzi</i> + SBRT PACIFIC-4	PD-L1 mAb + SBRT	PP	stage I/II NSCLC	>2027
<i>Imfinzi</i> + VEGF + TACE EMERALD-1	PD-L1 mAb + VEGFi +TACE		locoregional HCC	Q4 2023
<i>Imfinzi</i> +/- bevacizumab EMERALD-2	PD-L1 mAb +/- VEGFi		adjuvant HCC	H2 2026
<i>Imfinzi</i> +/- <i>Imjudo</i> + CTx POSEIDON	PD-L1 mAb +/- CTLA-4 mAb + CTx		1L NSCLC	Launched
<i>Imfinzi</i> combinations BEGONIA	PD-L1 mAb + paclitaxel/novel oncology therapies	Phase II LCM	1L TNBC	
<i>Imfinzi</i> combinations HUDSON	PD-L1 mAb + novel oncology therapies	Phase II LCM	post-IO NSCLC	
<i>Imfinzi</i> combinations NeoCOAST-2	PD-L1 mAb + novel oncology therapies	PP Phase II LCM	resectable NSCLC	
<i>Lynparza</i> MONO-OLA1	PARP inhibitor	PP	1L BRCAwt ovarian cancer	H2 2026
<i>Orpathys</i> + <i>Imfinzi</i> SAMETA	METi + PD-L1 mAb	PP	1L papillary renal cell carcinoma	H1 2026

Development Pipeline *continued*

Significant Life-cycle Management *continued*

Compound	Mechanism	Additional Information	Area Under Investigation	Data readout/ submission status
<i>Tagrisso</i> + <i>Orpathys</i> SAFFRON	EGFR TKI +METi	PP	advanced EGFRm NSCLC	H2 2026
<i>Tagrisso</i> + <i>Orpathys</i> SAVANNAH	EGFR TKI +METi	PP Phase II LCM	advanced EGFRm NSCLC	
<i>Tagrisso</i> +/- CTx NeoADAURA	EGFR TKI +/- CTx		neoadjuvant stage II/III resectable EGFRm NSCLC	Q4 2024
<i>Tagrisso</i> ADAURA2	EGFR TKI		EGFRm NSCLC stage Ia2-Ia3 following complete tumour resection	2027
<i>Tagrisso</i> combinations ORCHARD	EGFR TKI + multiple novel ONC therapies	PP Phase II LCM	2L EGFRm osimertinib-resistant NSCLC	
<i>Truqap</i>	AKT inhibitor	Phase II LCM	prostate cancer	
<i>Truqap</i> + abiraterone CAPItello-281	AKT inhibitor + NHA		PTEN deficient mHSPC	Accepted
<i>Truqap</i> + <i>Faslodex</i> + palbociclib CAPItello-292	AKT inhibitor + SERD + CDK4/6i		1L early relapse/ET resistant advanced HR+ breast cancer	2027

CVRM

<i>Wainua</i>	ligand-conjugated antisense	PP	patients with hereditary or wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR CM)	H2 2026
---------------	-----------------------------	----	---	---------

Respiratory & Immunology

<i>Breztri/Trixeo</i> (PT010) KALOS LOGOS	LABA/LAMA/ICS		asthma	Accepted
<i>Breztri/Trixeo</i> ATHLOS	LABA/LAMA/ICS		COPD cardiopulmonary exercise test (CPET) trial	H1 2026
<i>Breztri/Trixeo</i> THARROS	LABA/LAMA/ICS	PP	cardiopulmonary outcomes trial in COPD	>2027
<i>Fasenna</i> MANDARA	IL-5R mAb		eosinophilic granulomatosis with polyangiitis	Launched
<i>Fasenna</i> NATRON	IL-5R mAb		hypereosinophilic syndrome	Accepted
<i>Saphnelo</i> DAISY	type I IFN receptor mAb	PP	systemic sclerosis	2027
<i>Saphnelo</i> IRIS	type I IFN receptor mAb	PP	lupus nephritis	2027
<i>Saphnelo</i> JASMINE	type I IFN receptor mAb	PP	myositis	2027
<i>Saphnelo</i> LAVENDER	type I IFN receptor mAb	PP	cutaneous lupus erythematosus	2027
<i>Saphnelo</i> TULIP-SC	type I IFN receptor mAb	PP	systemic lupus erythematosus (subcutaneous)	Launched
<i>Tezspire</i> CROSSING	TSLP mAb	PP	eosinophilic esophagitis	H2 2026
<i>Tezspire</i> EMBARK, JOURNEY	TSLP mAb	PP	chronic obstructive pulmonary disease	>2027
<i>Tezspire</i> WAYPOINT	TSLP mAb	PP	nasal polyps	Launched

Rare Disease

<i>Koselugo</i> KOMET	MEK inhibitor	PP	neurofibromatosis type 1 adult	Launched
<i>Ultomiris</i>	anti-complement C5 mAb		haematopoietic stem cell transplant-associated thrombotic microangiopathy	H1 2026
<i>Ultomiris</i> ARTEMIS	anti-complement C5 mAb		cardiac surgery-associated acute kidney injury	H2 2026
<i>Ultomiris</i> AWAKE	anti-complement C5 mAb		delayed graft function	>2027
<i>Ultomiris</i> I CAN	anti-complement C5 mAb		immunoglobulin A nephropathy	H1 2026